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SUMMARY
Tissue-resident memory CD8+ T (Trm) cells share core residency gene programs with tumor-
infiltrating lymphocytes (TILs). However, the transcriptional, metabolic and epigenetic regulation 
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of Trm cell and TIL development and function is largely undefined. Here, we found that the 
transcription factor Bhlhe40 was specifically required for Trm cell and TIL development and 
polyfunctionality. Local PD-1 signaling inhibited TIL Bhlhe40 expression, and Bhlhe40 was 
critical for TIL reinvigoration following anti-PD-L1 blockade. Mechanistically, Bhlhe40 sustained 
Trm cell and TIL mitochondrial fitness and a functional epigenetic state. Building on these 
findings, we identified an epigenetic and metabolic regimen that promoted Trm cell and TIL gene 
signatures associated with tissue residency and poly-functionality. This regimen empowered the 
anti-tumor activity of CD8+ T cells and possessed therapeutic potential even at an advanced tumor 




The molecular regulation of CD8+ tissue-resident memory (Trm) cells and tumor-infiltrating 
lymphocytes (TILs) is incompletely understood. Li et al. reported that the transcription factor 
Bhlhe40 was required for Trm cell and TIL mitochondrial fitness and epigenetic programming. 
They further identified an epigenetic regimen promoting TIL functional program for cancer 
immunotherapy.
INTRODUCTION
Tissue resident memory CD8+ T (Trm) cells are a recently described population of CD8+ 
memory T (Tmem) cells, which permanently reside in non-lymphoid tissues (NLT) and 
rapidly respond to pathogen reinvasion (Ariotti et al., 2014; Kumar et al., 2017; Laidlaw et 
al., 2014). Generation and maintenance of Trm cells are regulated by a distinct set of 
transcription factors than those required for circulating Tmem cells, including Runx3, 
Notch, Blimp-1, Hobbit and Nur77 (Hombrink et al., 2016; Mackay et al., 2016; Milner et 
al., 2017; Skon et al., 2013). These transcription factors instruct a tissue-residency program 
that allows for the long-term retention and maintenance of Trm cells within NLT. Trm cells 
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have elevated expression of a number of effector molecules, including IFN-γ, TNF-α and 
Granzyme B (GzmB), which enable Trm cells to rapidly respond to stimulation and 
orchestrate protective immunity (Gebhardt et al., 2009; Jiang et al., 2012). Currently, the 
transcriptional regulation of “in situ” Trm cell functionality (rapid production of a range of 
effector molecules) is largely unknown. Of note, Trm cells and CD8+ tumor infiltrating 
lymphocytes (TILs) share a common core residency gene program (Milner et al., 2017). 
Furthermore, a Trm cell gene signature has been associated with improved patient survival 
in lung, breast and melanoma cancers (Ganesan et al., 2017; Guo et al., 2018; Savas et al., 
2018). However, the mechanisms by which Trm cell and TIL function and fitness are 
programmed or maintained are incompletely understood.
CD8+ T cell activation, effector differentiation and memory cell formation are closely 
associated with changes in the cellular metabolic programs. While effector T (Teff) cells 
mainly use aerobic glycolysis fueling their expansion and effector function, mitochondrial 
metabolism and oxidative phosphorylation (OXPHOS) are important in supporting Tmem 
cell maintenance and function (Bantug et al., 2018; Borges da Silva et al., 2018; Buck et al., 
2016; Pearce et al., 2009; Sena et al., 2013). Similarly, Trm cells require mitochondria-
dependent lipid oxidation for their long-term maintenance (Pan et al., 2017). Mitochondrial 
energy metabolism and fitness are also required for TIL fitness and function (Scharping et 
al., 2016; Zhang et al., 2017). However, the transcriptional regulation of mitochondrial 
metabolism in Trm cells and TILs are largely elusive. In addition to energy generation, 
mitochondria produce a variety of macromolecules important in cell physiological 
responses, including the regulation of gene expression (Mehta et al., 2017). For instance, as 
a critical substrate of histone acetylated modification, Acetyl-CoA is produced following 
fatty acid or pyruvate oxidation in mitochondria (Peng et al., 2016). Importantly, the 
increased presence of histone acetylation (such as H3K9 or H3K27 acetylation) and active 
chromatin state are tightly correlated with the function of CD8+ T cells (Henning et al., 
2018). To this end, the suppressive tumor microenvironment (TME) promotes TIL 
acquisition of a dysfunctional chromatin state in advanced tumor stages (Philip et al., 2017; 
Sen et al., 2016). The dysfunctional epigenetic programming may limit the efficacy of 
immunotherapies (Ghoneim et al., 2017). Thus, to achieve effective cancer immunotherapy, 
it is necessary to re-program the unresponsive T cell epigenetic state within the TME into a 
functional anti-tumor state.
Bhlhe40 is a stress-responsive transcription factor that is important in a number of cell 
physiological responses (Ma et al., 2013). Bhlhe40 expression in T helper (Th) cells 
modulates effector and pathogenic activities of Th1 and Th17 cells (Lin et al., 2016; Yu et 
al., 2018). Bhlhe40 overexpression in in vitro generated “memory” CD8+ T cells results in 
attenuated recall responses (Hu and Chen, 2013), but the physiological roles of Bhlhe40 in 
regulating CD8+ Teff and/or Tmem responses remain unclear. Here we demonstrate that 
Bhlhe40 is specifically required for the development, fitness and polyfunctionality of Trm 
cells and TILs. Bhlhe40 deficiency leads to impaired production of metabolites required for 
Acetyl-CoA synthesis, resulting in decreased Trm cell and TIL histone acetylation for the 
proper expression of functional molecules. Building on the findings, we have identified a 
regimen that can enhance wildtype (WT) and Bhlhe40−/− CD8+ T cell functionality and 
tissue residency gene programs through in vitro screening of an epigenetic library. Our 
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results provide mechanistic insights on the local regulation of Trm cell and TIL 
functionality, and offer a viable strategy for developing cancer immunotherapeutic strategies.
RESULTS
Resident CD8+ T cells highly express Bhlhe40
To explore Bhlhe40 function in CD8+ T cells, we first determined Bhlhe40 expression in 
WT CD8+ T cells following activation. We found that Bhlhe40 was potently upregulated in 
CD8+ T cells following activation (Figure S1A). Bhlhe40 was required for sustained 
expansion and effector molecule production by activated CD8+ T cells in vitro (Figures 
S1B–S1D). Further, there were pronounced differences in the transcriptional profiles 
between activated WT and Bhlhe40−/− CD8+ T cells (4 days post activation, d.p.a.) (Figure 
1A).Gene set enrichment analysis (GSEA) showed that Bhlhe40 modulated a core set of 
tissue signature genes recently discovered to be shared by Trm cells and TILs (Milner et al., 
2017), but not gene programs differentiating effector vs. memory or SLEC (short-lived 
effector cells) vs. MPEC (memory precursor effector cells) (Sarkar et al., 2008) (Figures 1B, 
S1E, S1F and Table S1). Further, analysis of single-cell RNA sequencing (scRNA-seq) data 
from human colorectal TILs (Zhang et al., 2018) found that BHLHE40hi TILs exhibited 
enrichment of the core tissue-residency gene signature relative to BHLHE40low TILs (Figure 
1C).
We next employed an acute influenza virus infection model and a melanoma (B16-F10 
expressing chicken ovalbumin (OVA), B16-OVA) transplantation model to study Bhlhe40 
function in Trm cell and TIL responses respectively. RNA-seq and prime-flow staining 
showed that Trm cells and TILs expressed higher Bhlhe40 compared to their splenic 
counterparts (Figure 1D and S1G). Moreover, the top 20 Bhlhe40-associated genes predicted 
by the GIANT (Genome-scale Integrated Analysis of gene Networks in Tissues) database 
(Greene et al., 2015) (Figure S1H) were enriched in both Trm cells and TILs compared to 
their splenic counterparts (Figure 1E). We compared BHLHE40 expression in tumor-reactive 
CD8+ T cells (CD45RO+PD-1+CD11a+ ) (Dronca et al., 2016) within TILs or peripheral 
blood mononuclear cells (PBMCs) from renal cell carcinoma (RCC) patients using prime-
flow analysis. Tumor-reactive TILs expressed higher BHLHE40 compared with their paired 
circulating counterparts (Figure S1I and Figure 1F left). Similarly, human lung Trm 
(CD103+) cells had increased BHLHE40 expression than Tmem cells in the PBMCs 
(Hombrink et al., 2016)(Figure 1F right). In addition, BHLHE40-associated genes were 
enriched in human TILs from colorectal cancer, liver cancer (HCC) and non-small cell lung 
cancer (NSCLC) compared to CD8+ T cells in the PBMCs (Guo et al., 2018; Zhang et al., 
2018; Zheng et al., 2017) (Figure 1G). These data suggest that Bhlhe40 and its associated 
genes are highly expressed in both mouse and human resident CD8+ T cells in the NLT or 
tumors compared to their lymphoid or circulating counterparts.
Intrinsic Bhlhe40 is critical for Trm cell fitness and function
We infected WT or Bhlhe40−/− mice with influenza A X31 (H3N2) strain, and examined 
influenza-specific effector and memory CD8+ T cell responses against MHC-I H2-Db 
restricted Nucleoprotein 366-374 peptide (NP366-374). Bhlhe40−/− mice exhibited 
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comparable frequency and numbers of NP366-374 Teff cells in the lungs (Teff-Lung) or 
spleens (Teff-SPL) as those of WT mice at 10 d.p.i. (Figures 2A and S2A). However, 
Bhlhe40 deficiency caused a marked decrease of frequencies and numbers of lung CD8+ 
Trm cells (Figures 2B and S2C). The magnitude of the CD8+ lung circulating (Tmem-Cir) 
or splenic Tmem (Tmem-SPL) cells in Bhlhe40−/− mice was comparable as those of WT 
mice (Figure 2B). Similar decrease of lung NP366-374 and PA224-233 (H2-Db-restricted 
polymerase 224-233 peptide) Trm cell responses was observed in Bhlhe40−/− mice 
following influenza PR8 (H1N1) virus infection (Thomas et al., 2006) (Figures 2C, 2D and 
S2D). CD69+CD103+ Trm cells also diminished following X31 or PR8 infection in 
Bhlhe40−/− mice (Figures S2C and S2D). The decreased Trm cell magnitude in Bhlhe40−/− 
mice was associated with enhanced Trm cell apoptosis (Figure 2E).
We next 1:1 mixed WT OTI (CD90.1+) and Bhlhe40−/− OTI (CD90.1+/CD90.2+), and 
transferred the mixed cells into WT mice. We then infected the mice with influenza PR8 
expressing ovalbumin (PR8-OVA) and followed the ratio of WT vs. Bhlhe40−/− OTI cells at 
10 and 35 d.p.i. (Figure 2F). The ratio of WT to Bhlhe40−/− OTI cells remained at ~1:1 in 
the spleen at the two time points, suggesting that CD8+ T cell-intrinsic Bhlhe40 was 
dispensable for the generation of splenic Teff and Tmem cells (Figure 2F). Bhlhe40 
deficiency caused a modest decrease of OTI effector cells in the lung at 10 d.p.i., but 
resulted in a marked impairment in the generation of lung Trm cells at 35 d.p.i. (Figures 2F 
and 2G). Moreover, Bhlhe40−/− Trm cells exhibited impairment in the production of IFN-γ 
(Figures 2H, and S2E). Notably, depletion of circulating CD8+ T cells with low dose anti-
CD8 or long-term FTY720 treatment at the memory stage did not alter the ratio of WT vs. 
Bhlhe40−/− Trm cells in the lungs (Figures S2F–S2H). Thus, Bhlhe40 likely acts on tissue-
resident CD8+ T cells to promote Trm cell formation, but probably not on recirculating 
memory T cells recently entering the lungs. To examine whether activated Bhlhe40−/− T 
cells also exhibit defects in Trm cell formation and/or maintenance, we stimulated WT or 
Bhlhe40−/− OTI cells in vitro and transferred the effector WT OTI (CD90.1+) and 
Bhlhe40−/− OTI (CD90.1+/CD90.2+) cells at the ratio of 1:1 into WT mice followed with 
PR8-OVA infection. Bhlhe40 deficiency in activated CD8+ T cells greatly diminished Trm 
cell formation, but only modestly affected Tmem-SPL responses (Figure S2I). We also 
generated T cell-specific Bhlhe40-deficient mice (Bhlhe40ΔT) and infected the mice with 
PR8. T cell-specific deficiency of Bhlhe40 resulted in decreased magnitude of total or 
CD69+CD103+ NP366-374 and PA224-233 lung Trm cells as well as diminished per cell 
experession of CD103 (Figures 2I, 2J, S2J, S2K and S2L). In addition, both Bhlhe40−/− and 
T cell-specific Bhlhe40 deficiency leaded to marked decrease of the production of effector 
molecules (IFN-γ, GzmB and TNF) by Trm, but not Tmem-SPL cells (Figures 2K, S2M). 
Thus, CD8+ T cell-autonomous Bhlhe40 is specifically required for Trm cell formation, 
fitness and functionality. As a result, Bhlhe40−/− mice that were previously infected with 
X31 exhibited defects in Trm cell-mediated protection against a lethal secondary PR8 
challenge in the presence of FTY720, which blocked circulating memory T cell migration to 
the lungs (Iborra et al., 2016) (Figures 2L). Further, Bhlhe40−/− mice that were previously 
infected with PR8 had defects in Trm cell-mediated protection against secondary X31 
challenge (Figures 2M).
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Bhlhe40 is vital for TIL fitness and poly-functionality
Trm cells and TILs share a core tissue residency and function gene signature (Milner et al., 
2017). To this end, we subcutaneously implanted B16-OVA into WT or Bhlhe40−/− mice, 
and checked TIL responses. Bhlhe40−/− mice showed decreased total and antigen-specific 
(H2-Kb OVA257-264 tetramer+) TILs at day 14 and 18 post tumor transplantation (d.p.t.i.) 
(Figures 3A, 3B, and S3A). Bhlhe40−/− TILs had increased apoptosis and decreased IFN-γ 
and GzmB production (Figures 3C, 3D), yet showed comparable proliferative responses as 
WT TILs (Figure S3B). In contrast, Bhlhe40−/− splenic CD8+ T cells exhibit similar levels 
of apoptosis, IFN-γ or GzmB production as their WT counterparts (Figures 3C and 3D).
T cells capable of producing multiple effector molecules are poly-functional and associated 
with better cancer control (Yuan et al., 2008; Zhao et al., 2016a). We thus evaluated the 
poly-functionality of WT and Bhlhe40−/− TILs by measuring five effector molecules in TILs 
(IFN-γ, TNF-α, GzmB, CCL3 and CCL4). Bhlhe40−/− TILs showed decreased frequencies 
of cells simultaneously producing multiple effector molecules (Figures 3E and S3C). 
Importantly, Bhlhe40−/− TILs did not have increased PD-1, TIM-3 or CTLA4 compared to 
WT TILs (Figure S3D). Notably, “stem-like” TILs (PD-1int TCF1+ CXCR5+) expressed 
much lower Bhlhe40 than PD-1hi TILs and “exhausted” PD-1hi TIM-3+ TILs (Figure S3E), 
which is consistent with the reported findings that TCF1− TILs have enrichement of Trm cell 
signature genes and had higher effector molecule expression compared to TCF1+ “stem-
like” TILs (Kurtulus et al., 2019; Siddiqui et al., 2019). Within the PD-1hi TIM-3+ TIL 
population, Bhlhe40hi TILs had higher Ifng and enriched with core Trm cell and TIL 
residency gene signature relative to Bhlhe40low TILs (Figures S3F–S3I) (Singer et al., 2016) 
(Zhang et al., 2018), suggesting that the amount of Bhlhe40 expression in this TIL 
population may correlate with their residual function in situ. Altogether, our data indicate 
that Bhlhe40 is key for maintaining TIL function. As a result, Bhlhe40−/− mice had 
increased tumor burden following transplantation with multiple tumor cell lines including 
B16-OVA, MC-38 (Murine colon adenocarcinoma cells) and LLC (Lewis Lung Carcinoma) 
(Figures 3F–3H).
We then 1: 1 mixed WT and Bhlhe40−/− OTI cells and transferred into B16-OVA bearing 
mice. While Bhlhe40−/− OTI cells competed well with WT OTI cells inside the spleen, 
Bhlhe40 deficiency resulted in progressive and drastic OTI cell loss inside the tumor, 
suggesting that intrinsic Bhlhe40 is critical for TIL maintenance during tumor progression 
(Figures 3I and S3J). Importantly, effector T cell migration to tumor was Bhlhe40-
independent (Figure S3K). Further, Bhlhe40ΔT mice exhibited decreased antigen-specific 
TILs, and diminished CD69 and CD103 expression (Figures 3J, 3K and S3L). TILs from 
Bhlhe40ΔT mice also showed diminished expression of multiple effector molecules (Figure 
3L). Consequently, Bhlhe40ΔT mice had enhanced tumor growth (Figure 3M). Conversely, 
ectopic Bhlhe40 expression in OTI cells facilitated T cell accumulation inside tumor and 
decreased B 16-OVA tumor burden (Figures 3N–3O and S3M–S3N). Thus, T cell-intrinsic 
Bhlhe40 is essential for TIL residency, fitness and function.
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Bhlhe40 deficiency abrogated the therapeutic effects of anti-PD-L1 blockade
A number of the mediators including IL-1β, TNF, PGE2 and IL-15 promoted Bhlhe40 
expression in CD8+ T cells (Figure S4A). Further, CD28 co-stimulation boosted Bhlhe40 
expression in CD8+ T cells (Figure S4B). It is thus possible that one or multiple of these 
factors could promote Bhlhe40 expression in NLT and/or tumors in vivo. Recent advances in 
anti-PD (PD-1 or PD-L1 blockade) therapy have revolutionized cancer treatment (Dong et 
al., 2002; Topalian et al., 2012), although the mechanisms underlying the efficacy of anti-PD 
blockade are still incompletely defined. We hypothesized that PD-L1-PD-1 interaction may 
inhibit Bhlhe40 expression within TME to dampen TIL effector activity in situ. To explore 
the idea, we transplanted B16-OVA into both flanks of WT mice, then injected either anti-
PD-L1 or control IgG intratumorally into the bi-lateral tumors from 5 d.p.t.i. (Figure 4A). 
Local PD-L1 blockade decreased tumor size and increased Bhlhe40 expression in TILs 
(Figures 4A, S4C), suggesting that PD-1 signaling suppresses TIL Bhlhe40 expression in 
situ. Importantly, co-transfer of congenically distinct WT and Pdcd1−/− OTI cells 
demonstrated that CD8+ T cell-intrinsic PD-1 signaling suppressed Bhlhe40 expression in 
TILs (Figure S4D). Anti-PD-L1 treatment increased TIL survival and IFN-γ production in 
WT mice (Figures 4B, 4C). However, Bhlhe40 deficiency abrogated the effects (Figures 4B, 
4C). In accordance, α-PD-L1 controlled tumor growth in WT mice, but not in Bhlhe40−/− 
mice (Figures 4D, S4E). T cell-specific Bhlhe40 deficiency also abrogated T cell 
reinvigoration and the therapeutic effects of α-PD-L1 treatment (Figures 4E–4G). These 
data indicate that local PD-1 signaling suppresses Bhlhe40 expression in TILs, and Bhlhe40 
is critical for TIL reinvigoration and therapeutic efficacy of anti-PD therapy.
Bhlhe40 directs mitochondrial regulation of Trm cell and TIL active chromatin status
We next performed RNA-seq analysis on WT and Bhlhe40−/− OTI Trm cells isolated from 
PR8-OVA infected mice. Bhlhe40 was required for modulating the expression of a large 
number of Trm cell-associated genes (Figures S5A, S5B). Nanostring analysis confirmed 
that Bhlhe40 was needed for the expression of genes necessary for Trm cell formation 
and/or maintenance including Runx3 and Notch 1, 2 (Hombrink et al., 2016; Milner et al., 
2017) (Figures S5C, D). Notably, the expression of immune-associated genes was relatively 
similar between WT and Bhlhe40−/− Tmem-SPL cells, indicating that Bhlhe40 
“preferentially” regulates Trm cell function (Figures S5C and S5D). Pathway analysis of the 
genes downregulated in Bhlhe40−/− Trm cells (compared to WT Trm cells) revealed that the 
mitochondrion was the primary target of Bhlhe40-directed gene expression (Figure 5A). 
Bhlhe40−/− Trm cells had diminished expression of genes encoding components of 
mitochondrial membrane or genes involved in mitochondrial metabolism and/or OXPHOS, 
which are vital for fueling Tmem cells and TILs (Pearce et al., 2009; Scharping et al., 2016) 
(Figures 5B, S5E). Consistently, analysis of scRNA-seq data from mouse (Singer et al., 
2016) and human (Zhang et al., 2018) PD-1hi TIM-3+ CXCR5− TIL population, which 
express considerable amount of Bhlhe40, has revealed that Bhlhe40hi TILs had enrichment 
of OXPHOS genes relative to Bhlhe40low TILs (Figures S5R). Bhlhe40 deficiency resulted 
in decreased expression of a number of nuclear-encoded electron transport genes (Figure 5 
C). Chromatin immunoprecipitation (ChIP) experiments confirmed that Bhlhe40 directly 
bound to mitochondrial genes in both CD8+ and CD4+ T cells (Figure 5D, S5F) (Huynh et 
al., 2018). Thus, Bhlhe40 functions to promote mitochondrial gene transcription in Trm 
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cells. Consistently, Bhlhe40−/− Trm cells exhibited lower oxygen consumption rate (OCR), 
but not extracellular acidification rate (ECAR) (Figure 5E). Electron microscopic analysis 
revealed that both Bhlhe40−/− Trm cells and TILs had enhanced mitochondrial damage 
(Figures 5F and 5G). Bhlhe40−/− TILs also had lower OCR (Figure S5G). In contrast, WT 
Tmem-SPL and Bhlhe40−/− Tmem-SPL cells expressed comparable amounts of 
mitochondrial genes and had similar mitochondrial morphology (Figure 5F and S5H).
Beyond OXPHOS, mitochondria play key roles in biosynthesis and epigenetic regulation of 
gene expression (Mehta et al., 2017). To this end, we employed an in vitro dendritic cell 
(DC) and T cell culture model to examine the downstream metabolic and epigenetic 
consequences of dysfunctional mitochondria in Bhlhe40−/− T cells. We confirmed that 
Bhlhe40 was required for the maintenance of CD8+ T cell mitochondrial fitness and 
metabolism in the in vitro model as Bhlhe40−/− CD8+ T cells showed diminished OCR, 
damaged mitochondria compared to their WT counterparts at 4 d.p.a. (Figures S5I and S5J). 
As a result, Bhlhe40−/− CD8+ T cells had lower cellular ATP concentration than WT CD8+ 
T cells at 4 d.p.a. (Figure S5K). We then measured more than 400 metabolites in WT and 
Bhlhe40−/− CD8+ T cells at 4 d.p.a. by Quadrupole Time-of-Flight Mass Spectrometry 
(QTOF/MS). This metabolomics analysis revealed that there was a reduction of metabolites 
in the tricarboxylic acid (TCA) cycle, butanoate metabolism, amino acid (AA) and pyruvate 
metabolic pathways in Bhlhe40−/− CD8+ T cells compared to WT CD8+ T cells (Figure 5H). 
Quantitative measurement of TCA metabolites by Gas chromatography–mass spectrometry 
(GC/MS) confirmed that Bhlhe40−/− T cells had a global decrease in TCA metabolites 
(Figure 5I). Of note, stable isotope tracer analysis (SITA) analysis found that there were no 
significant defects for the synthesis of citrate pools from incorporated pyruvate or glutamine 
in Bhlhe40−/− CD8+ T (Figure S5L), but the pyruvate uptake was relatively decreased in 
Bhlhe40−/− CD8+ T cells (Figure S5M), which is consistent with the diminished pyruvate 
transporter gene (Slc16a1) expression in Bhlhe40−/− CD8+ T cells (Figure S5N).
Those downregulated metabolic pathways (TCA, butanoate and AA metabolisms) and ATP 
are important in the biosynthesis of Acetyl-CoA, a critical substrate of histone acetylation 
that is required for the active chromatin state in cells (Wellen et al., 2009). Indeed, 
Bhlhe40−/− CD8+ T cells showed lower cellular Acetyl-CoA concentration compared to WT 
CD8+ T cells (Figure 5J). Consequently, total acetylated H3 was decreased in cultured 
Bhlhe40−/− CD8+ T cells (Figure 5K). Importantly, Bhlhe40−/− Trm cells and TILs exhibited 
diminished acetylated H3 compared to their WT counterparts (Figure 5K). Thus, Bhlhe40 
deficiency decreased cellular Acetyl-CoA concentration and histone acetylation in CD8+ T 
cells, which likely caused the impaired expression of effector molecules and defective anti-
viral and antitumor functionality in vivo. Conversely, ectopic Bhlhe40 expression modestly 
increased mitochondrial respiratory chain gene expression and promoted histone H3 
acetylation (Figures S5P and S5Q), indicating that Bhlhe40 may determine histone 
acetylation in the functional gene loci of CD8+ T cells. In accordance, we observed marked 
decrease of acetyl H3K9 and acetyl H3K27 in the Ifng locus in Bhlhe40−/− CD8+ T cells 
(Figure 5L). We also noticed decreased acetyl H3K27 in the loci of mitochondrial complex 
genes (Cox6a1 and Atp5e) (Figure S5O). Taken together, these data indicate that Bhlhe40 is 
critical for the maintenance of Trm cell and TIL mitochondrial fitness and function, thereby 
promoting active chromatin modifications for their in situ functionality.
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Identification of an epigenetic regimen promoting a CD8+ T cell residency and functional 
program
We reasoned that the provision of extra TCA intermediates such as pyruvate or citrate may 
restore IFN-γ production by Bhlhe40−/− CD8+ T cells through the promotion of Acetyl-CoA 
production and histone acetylation. However, extra TCA intermediate supplementation, 
including pyruvate, citrate, methyl-pyruvate (MP) and dimethyl-alpha ketoglutarate (DMK) 
failed to promote IFN-γ production by Bhlhe40−/− CD8+ T cells (Figures S6A and S6B), 
suggesting that diminished cellular citrate concentration may not be the primary reason for 
the impaired IFN-γ production in Bhlhe40−/− T cells. To this end, ATP citrate lyase (ACLY) 
is required for Acetyl-CoA production from citrate (Wellen et al., 2009). Consistent with the 
inability of pyruvate or citrate to rescue Bhlhe40−/− CD8+ T cell IFN-γ production, 
Bhlhe40−/− CD8+ T cells had diminished expression of ACLY (Figures S6C, S6D). These 
data suggest that direct targeting the downstream epigenetic machinery may be a viable 
approach to rescue IFN-γ production by Bhlhe40−/− CD8+ T cells. To this end, we sought to 
identify epigenetic modifiers that can directly stimulate IFN-γ production in activated CD8+ 
T cells. To do this, we activated IFN-γ-YFP CD8+ T cells in vitro and screened an 
epigenetic library to identify chemicals that can promote IFN-γ expression in activated T 
cells (Figure 6A). A few chemicals, mainly histone deacetylase inhibitors (HDACi), 
especially Tubastatin A (TA) could promote IFN-γ production with low cellular toxicity, 
although a large number of other HDACi failed to do so, demonstrating a unique effect of 
TA (Figures 6A, 6B). Notably, TA promoted, but did not fully restore IFN-γ production by 
Bhlhe40−/− CD8+ T cells (Figure S6E). We reasoned that the supplementation of acetate 
(Ac), which is a TCA cycle-independent substrate for Acetyl-CoA synthesis (Zhao et al., 
2016b), could further boost histone acetylation and cytokine production by Bhlhe40−/− 
CD8+ T cells. Indeed, TA and Ac cooperatively enhanced IFN-γ production by Bhlhe40−/− 
CD8+ T cells (Figure 6C). However, TA combined with other metabolic substrates such as 
pyruvate and citrate failed to do so (Figure S6F).
TA and Ac cooperatively promoted WT or Bhlhe40−/− CD8+ T cell poly-functionality and 
the expression of a number of cytokines and cytotoxic molecules (Figure 6D and 6E). 
Furthermore, TA/Ac treatment increased CD69 and CD103 expression, and a large number 
of genes associated with Trm cell and TIL formation and residency programs in both WT 
and Bhlhe40−/− CD8+ T cells (Figures 6F, 6G and S6G). Moreover, those upregulated genes 
following TA/Ac treatment showed enrichment in WT Trm cells compared to Bhlhe40−/− 
Trm cells (Figure S6H). Thus, we have identified a metabolic and epigenetic regimen 
capable of promoting the Bhlhe40-dependent CD8+ T cell residency and functionality gene 
programs. Consistent with this idea, TA/Ac treatment resulted in increased histone H3 
acetylation and increased H3K9 acetylation in Ifng, Gzmb and Itgae (CD103) loci in CD8+ 
T cells (Figures 6H and 6I).
Epigenetic modification of resident CD8+ T cell functionality promotes superior tumor 
control
We reasoned that the epigenetic modification of CD8+ T cell residency and functionality 
programs by TA/Ac treatment may empower Bhlhe40−/− CD8+ T cell antitumor activities. 
To this end, B16-OVA bearing mice were adoptively transferred with WT or Bhlhe40−/− 
Li et al. Page 9













effector OTI cells at 6 d.p.t.i. Compared to WT effector OTI cells, Bhlhe40−/− OTI cells 
failed to control tumor growth (Figure 7A). However, TA/Ac treatment enabled Bhlhe40−/− 
OTI cells to inhibit tumor growth (Figures 7A, S7A), suggesting that TA/Ac treatment 
reinvigorated Bhlhe40−/− CD8+ T cell antitumor activities. The progressive growth of tumor 
is accompanied with enhanced immunosuppression to effector T cells by TME (Rabinovich 
et al., 2007; Scharping et al., 2016). Consistent with the idea, even WT effector OTI cells 
had limited therapeutic efficacy when transferred into mice with a large tumor burden at 10 
or 12 d.p.t.i. (> 120 mm2), which was in sharp contrast to results of WT effector OTI 
transfer at 6 d.p.t.i. (Figures 7A, 7B, S7B and S7C). We reasoned that the direct modulation 
of CD8+ epigenetic status by TA/Ac treatment may empower WT CD8+ T cell anti-tumor 
functionality under the strong immunosuppression rendered by TME at the advanced tumor 
stage. Consistent with this hypothesis, TA/Ac treatment potentiated WT effector OTI cells to 
control tumor growth even at these advanced tumor stages (Figures 7B, S7B and S7C).
TILs develop a fixed dysfunctional chromatin state at advanced tumor stages, which 
diminishes their anti-tumor capability (Philip et al., 2017). Therefore, to provoke TIL 
function, we injected TA/Ac intratumorally at 11 d.p.t.i. following B16-OVA transplantation, 
when tumor area is larger than 100 mm2. TILs showed increased histone H3 acetylation 
following TA/Ac treatment in vivo (Figures 7C, S7D), indicating that TA/Ac may at least 
partially reverse inaccessible chromatin states of dysfunctional TILs (Henning et al., 2018). 
Further, TA/Ac treatment augmented IFN-γ and CCL3 production by TILs (Figure 7D). 
PD-1 blockade shows limited effects in reversing the dysfunctional chromatin states in 
exhausted CD8+ T cells (Pauken et al., 2016). This epigenetic fate inflexibility of TILs may 
limit the efficacy of anti-PD immunotherapies (Pauken et al., 2016). Consistent with the 
concept, anti-PD-L1 treatment inhibited tumor growth when inoculated at 5 d.p.t.i. (Figure 
S4C), but failed to do so when inoculated at 11 d.p.t.i. (Figure 7E). TA/Ac treatment 
promoted tumor control in mice with a large tumor burden at 11 d.p.t.i. (Figure 7E). 
Furthermore, TA/Ac treatment showed efficacy to control MC-38 tumor growth when 
inoculated at 15 d.p.t.i. (tumor > 100 mm2) (Figure 7F). TA/Ac treatment did not exhibit 
synergistic effects with anti-PD therapy (Figure S7E), supporting the view that TA/Ac may 
target the downstream pathways of anti-PD therapy. We have also implanted B16-OVA 
tumor to both flanks of the mouse and treated the bi-lateral tumors with TA/Ac or vehicle at 
10 d.p.t.i. Local treatment of TA/Ac resulted in smaller sizes of tumor compared to the distal 
tumor received vehicle treatment in the same WT mouse (Figure 7G), suggesting that TA/Ac 
treatment likely targets TILs directly rather than circulating CD8+ T cells to control tumor 
growth. We performed similar treatment regimen in Bhlhe40ΔT mice (Figure 7H). TA/Ac 
treatment promoted Trm cell-like TIL (CD69+CD103+) presence, mitochondrial gene 
expression and histone H3 acetylation in Bhlhe40-deficient TILs (Figures S7F–S7H). 
Consistently, TA/Ac treatment lowered tumor burden compared to the distal tumor received 
vehicle treatment in the same mouse (Figure 7H and S7I). Importantly, CD8+ T cell 
depletion largely abolished the efficacy of TA/Ac treatment (Figure 7I), suggesting that 
TA/Ac promoted CD8+ T cell-dependent tumor control at the advanced cancer stage. 
Although it is still possible that the direct tumoricidal effects of TA may contribute to the 
therapeutic effects of TA/Ac treatment.
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Here we have shown that Bhlhe40 maintains Trm cell and TIL mitochondrial fitness and 
metabolism, thereby promoting an active chromatin state for Trm cell and TIL residency and 
functionality. An important question is why Bhlhe40 specifically affects tissue-resident 
CD8+ T cell function over circulating CD8+ T cells. This could be linked to the higher 
expression of Bhlhe40 in Trm cells and TILs compared to their circulating counterparts. In 
addition, tissue or tumor microenvironment may further provoke CD8+ T cells relying on 
Bhlhe40 for their survival and function. Mucosal tissues and tumors have limited nutrients 
(such as glucose) and/or under hypoxic or oxidative conditions (Chang et al., 2015; Colgan 
et al., 2016). These local environments would likely cause stresses to resident T cells that 
originate from nutrient-rich or less stressful lymphoid organs. As a stress responsive protein, 
Bhlhe40 is likely only required for the survival and function of CD8+ T cells under stress 
conditions.
Mitochondrial fitness in TILs is dampened compared to their circulating and secondary 
lymphoid compartments (Scharping et al., 2016). In the absence of Bhlhe40, TIL 
mitochondria damage was further exacerbated, suggesting that Bhlhe40 is critical for 
maintaining the residual function of mitochondria in TILs. Recent evidence has revealed 
marked cellular heterogeneity within TILs (Azizi et al., 2018; Li et al., 2019). Notably, a 
population of stem-like TCF1+ TILs has been demonstrated to be important in mediating the 
proliferative response to anti-PD therapy (Kurtulus et al., 2019; Siddiqui et al., 2019). We 
found that TCF1+ TILs expressed lower amount of Bhlhe40 compared to PD1 hi or PD-1hi 
TIM-3 + TILs. These data are consistent with the results that TCF1− TILs exhibit Trm cell-
gene program and express higher Ifng and GzmB compared to the stem-like TCF1+ TILs 
(Kurtulus et al., 2019; Siddiqui et al., 2019). Thus, Bhlhe40 may be selectively important for 
the fitness and function of TCF1− Trm-like TILs (Savas et al., 2018; Siddiqui et al., 2019). 
In support, Bhlhe40 expression in both mouse and human PD-1hi TIM-3+ CXCR5− TILs 
positively correlated with Ifng expression, tissue residency and mitochondrial metabolism 
gene signatures. Thus, there may be further phenotypic and functional heterogeneity within 
this “exhausted” TIL population as defined by the amount of Bhlhe40 expression. Among 
these TILs, Bhlhe40hi cells may represent “true” Trm-like TILs that still possess residual 
mitochondrial function and exhibit anti-tumor effector activities in situ. Further 
revitalization of Bhlhe40-dependent mitochondrial function and effector activities in Trm-
like TILs is likely a key for effective cancer immunotherapy.
CD8+ TILs progressively develop a fixed dysfunctional chromatin state in advanced tumor 
stages and TIL epigenetic inflexibility may limit the efficacy and durability of anti-PD 
therapies (Philip et al., 2017). Consistent with the idea, we found that PD-L1 blockade failed 
to provide therapeutic effects when inoculated at the advanced tumor stages. To tackle this 
major barrier of anti-PD therapy, we have employed in vitro functional screening and 
identified an epigenetic regimen that is capable of reinvigorating TIL antitumor function in 
large tumors, potentially through direct targeting on the TIL epigenetic state. Thus, 
epigenetic targeting on TIL function may represent a promising strategy to overcome tumor 
anti-PD resistance. In our screen, Tubastatin A represents a fairly unique HDAC inhibitor 
that promoted IFN-γ production by activated CD8+ T cells without causing overt cell death. 
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Tubastatin A is a potent HDAC6 inhibitor but also possesses inhibitory activities against 
HDAC8 (M et al., 2016). It is possible that Tubastatin A functions to inhibit HDAC6 activity 
to promote CD8+ T cell function in our setting. However, HDAC6-deficient CD8+ T cells 
express comparable amount of IFN-γ as WT CD8+ T cells (Nunez-Andrade et al., 2016). 
Thus, Tubastatin A may target both HDAC6 and HDAC8 to increase CD8+ T cells effector 
function. Of note, the provision of acetate, which is a substrate supporting Acetyl-CoA 
synthesis even in the absence of ACLY (Peng et al., 2016; Zhao et al., 2016b), cooperated 
with Tubastatin A to further enhance CD8+ T cell residency and poly-functionality gene 
programs in vitro. Likewise, emerging data have suggested that acetate and other short chain 
fatty acid may promote CD8+ T cell metabolism and function (Balmer et al., 2016; Qiu et 
al., 2019; Trompette et al., 2018).
Even though TA/Ac treatment improves CD8+ T cell effector function, the treated tumors 
still steadily progress albeit at a slower rate than tumors receiving vehicle control. It is 
possible that epigenetic targeting in TILs alone is not sufficient to achieve complete tumor 
regression, which would suggest that regimens that can increase continuous CD8+ T cell 
infiltration to the tumor may be needed to achieve superior tumor control. Tumor cells may 
also develop many adaptive resistance strategies to promote their growth even with strong 
immune activation (Hamieh et al., 2019; Poggio et al., 2019; Ribas, 2015; Sharma et al., 
2017). Notably, TA/Ac treatment not only enhances Bhlhe40−/− CD8+ T cell effector and 
resident gene expression but also promotes the expression of these genes in WT CD8+ T 
cells (albeit to a lesser extent), suggesting that TA/Ac does not selectively target on 
Bhlhe40−/− CD8+ T cells. In addition, direct manipulation of CD8+ T cell epigenetic state by 
TA/Ac likely will not completely reverse the multiple defects of mitochondrial function and 
metabolism caused by Bhlhe40 deficiency. Future studies are required to determine the 
extent of rescue of TA/Ac treatment in revoking impaired Bhlhe40−/− Trm cell and TIL 
responses, particularly on Trm cell and TIL long-term persistence in vivo. Nevertheless, the 
appropriate combinations of epigenetic modifiers with certain metabolites may represent 
promising approaches for maximally reinvigorating tissue or tumor-resident CD8+ T cell 
antiviral or antitumor activities.
Overall, we have identified a mechanism for programming the mitochondrial and epigenetic 
regulation of resident CD8+ T cell functionality in situ. This mechanism is critically 
important in the antiviral and antitumor activities of Trm cell and TILs respectively. Building 
on these findings, we propose a potential metabolic and epigenetic modality to activate a 
functional CD8+ T cell residency gene signature that mediates effective cancer 
immunotherapy at an advanced tumor stage.
STAR Methods
LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directedto and will be 
fulfilled by the Lead Contact (sun.jie@mayo.edu).
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Mice, infection and tumor transplantation: Mice on a C57BL/6 background were used in 
this study. Bhlhe40−/− mice were originally generated previously as reported (Sun et al., 
2001). Bhlhe40tmIa(KOMP)Wtsl mice were obtained from MMRRC and were crossed to FLP 
delete strain (JAX) mice to generate Bhlhe4dv/l mouse strain. Bhlhe40f//l mice were then 
crossed with CD4-cre mice (JAX) to generate Bhlhe40Kl mice. IFN-γ-YFP (GREAT) 
reporter mice, OTI Thyl.1 mice and C57BL/6 mice were obtained from the Jackson 
Laboratory. Thy1.1+ Thy1.2+ Bhlhe40−/− OTI mice were generated by crossing Bhlhe40−/− 
mice with Thy1.1+ OTI mice. Thy1.1+ Thy1.2+ Pdcd1−/− OTI mice were generated by 
crossing Pdcd1−/− mice with Thy1.1+ OTI mice. All animal protocols were approved by the 
Institutional Animal Care and Use Committees (IACUC) of the Mayo Clinic or the Indiana 
University School of Medicine. Influenza A/PR8/34 (~200 pfu/mouse in the primary 
infection and ~1χ104 pfu/mouse in the secondary infection), recombinant PR8 expressing 
Ovalbumin SINNFEKL peptide (PR8-OVA) (~500 pfu/mouse) and Influenza A X31 (~800 
pfu/mouse in the primary infection and ~8χ104 pfu/mouse in the secondary infection) 
infection were performed by intranasal (i.n.) under anesthesia as described before (Sun et al., 
2009).
Cell Lines and tumor implantation: Tumor cell lines were from the laboratory of Haidong 
Dong and reported before (Dronca et al., 2016; Tang et al., 2018), including B16-OVA 
melanoma, Lewis lung carcinoma (LLC), and MC38 colon adenocarcinoma. B16-OVA cell 
line and MC38 cell line were cultured in RPMI-1640 with 20mM HEPES and 10% FBS. 
The LLC cell line was cultured in DMEM with 20mM HEPES and 10% FBS. Tumor cells 
(B16-OVA, LLC and MC38) were subcutaneously injected into the flank of mice (5 χ 105 
cells/mouse). Tumor size was measured every 2 days starting from day 6. Tumor size was 
calculated as length χ width. Mice with tumor size larger than 400 mm2 or ulcerative were 
euthanized and counted as mortality.
Intravascular CD8+ T cell labeling for identification of Trm cells: Mice were injected i.v. 
with 1.5 μg of anti-CD45 diluted in 200 μL of sterile PBS as previously described (Anderson 
et al., 2014). Mice were euthanized and tissues were collected five minutes after injection of 
the i.v. Ab. Tissues were dissociated in 37°C for 30 min with Gentle-MACS (Miltenyi). 
Lung circulating CD8+ T cells are i.v. Ab+ and lung-resident CD8+ T cells are defined by i.v. 
Ab−.
T cell adoptive transfer: For WT OTI T cell transfer, Thy1.1 WT OTI cells were purified 
via CD8a-microbeads (Miltenyi). 5 χ 104 cells were transferred into C57BL6 mice. For 
competition experiment, wild-type and Bhlhe40 −/− OTI cells were mixed as ratio of 1:1, and 
were adoptive transferred into recipient mice subsequently infected with PR8-OVA (1 χ 105 
mixed cells / mouse), or were transferred into B16-OVA bearing mice (2 χ 106 mixed cells / 
mouse).
Quantitative RT-PCR: Total RNA were extracted from cells as indicated in the text with 
Total RNA purification kit (Sigma) and treated with DNase I (Invitrogen). Random primers 
and MMLV reverse transcriptase (Invitrogen) were used to synthesize first-strand cDNAs 
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from equivalent amounts of RNA from each sample. These cDNA was subjected to realtime-
PCR with Fast SYBR Green PCR Master Mix (Applied Biosystems). qPCR was conducted 
in duplicates in QuantStudio3 (AppliedBioscience). Data were generated with the 
comparative threshold cycle (Delta CT) method by normalizing to hypoxanthine 
phosphoribosyltransferase (HPRT). Bhlhe40 primers were purchased from IDT (Assay ID. 
Mm.PT.58.10417747). Sequences of primers used in the studies are listed as following. 
Primer sequences: Hprt-F: CTCCGCCGGCTTCCTCCTCA, Hprt-
R:ACCTGGTTCATCATCGCTAATC. Acly-F: TTCGTCAAACAGCACTTCC, Acly-R: 
ATTTGGCTTCTTGGAGGTG.
Tumor and lung tissue dissociation: Tumor tissues were harvested and weighed at 
indicated days after implantation. Tumor tissues were dissociated into single cell suspension 
by GentleMACS (Miltenyi Biotech) following the instruction of mouse Tumor Dissociation 
Kit (Miltenyi). Spleens were also isolated and dissociated into single cell suspension using 
70 μm cell strainer (BD Biosciences). Lung tissues were harvested and digested with 
Collagenase Type 2 for 30 min as described previously (Yao et al., 2015).Tumor, lung and 
spleen single cell suspension were further passed through 70pm cell strainer one time before 
next step operation.
CD8+ T cell culture in vitro: Bone marrow-derived dendritic cells (BMDC) were 
differentiae ex vivo in the presence of GM-CSF (20ng/ml) for 6 days as described(Sun and 
Pearce, 2007). CD8+ T cells were purified from spleen and lymph nodes with the CD8a 
(Ly-2) MicroBeads (Miltenyi Biotech). The purified CD8+ T cells were cocultured with 
BMDC as the ratio of 10:1 (T:DC) in round bottom 96-well plate, and were stimulated with 
soluble anti-CD3 (1 μg/ml) as described before(Sun et al., 2011). For cytokines stimulation, 
IL-1 β (10 ng/ml), IL-15 (20 ng/ml), IL-21 (10 ng/ml), IL-7 (10 ng/ml), IL-33 (10 ng/ml), 
TNF (10 ng/ml), TGFβ (10 ng/ml), IL-10 (10 ng/ml) and PGE2 (2 μM) were added in to the 
co-culture system. For anti-CD28 stimulation, purified CD8+ were stimulated with plat-
bound anti-CD3 (2 μg/ml), soluble anti-CD28 (10 μg/ml) were presented into the culture 
system. For metabolites and HDACi treatment, in vitro cultured CD8+ T cells were treated 
with pyruvate (1mM), citrate (5mM), methyl-pyruvate (MP) (1mM) and dimethyl-alpha 
ketoglutarate (DMK) (1mM), acetate (20mM) and Tubastatin A (10 μM) at 3 d.p.a. and 
cytokine production were measured at 4 d.p.a.
Retroviral Transduction: CD8+ T cells were stimulated with α-CD3 and α-CD28. At day 
1 of the culture, cells were transduced with retroviruses (Lin et al., 2014) through spin 
infection (2,500 rpm, 90 min) in the presence of 5μg/ml polybrene as previously described 
(Yao et al., 2013). After transduction, cells were analyzed by flow cytometry, and transferred 
into B16-OVA bearing recipients (5 d.p.t.i.) on day 2 post transduction.
Polyfunctional T cell analysis: Single cell suspension were stimulated with PMA (0.1 
μg/ml) and Ionomycin (1 μg/ml) (Sigma) or OVA257-264 peptide (Anaspec, 1 μg/ml) or 
NP366-374 peptide (Anaspec,1 μg/ml) for 5h in the presence of 2μM monensin (BD 
Biosciences), and then stained with APC-CY7 conjugated anti-CD8. Cells were fixed and 
permeabilized by fixation buffer and intracellular staining perm wash buffer (Biolegend), 
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and stained with anti-IFN-γ, anti-MIP-1α, anti- MIP-β, anti- TNF-α, and anti-GzmB as 
described(Yao et al., 2013). Then Boolean gates were applied to analyze (Precopio et al., 
2007).
Cell sorting: Tumor infiltrated CD8+ T cells were purified with the CD8a (Ly-2) 
MicroBeads (Miltenyi Biotech), and then were stained with Percp/CY5.5 conjugated anti-
CD3, APC conjugated anti-CD8β, BV421 conjugated anti-CD44, CD3+ CD8+ CD44+ or 
CD3+ CD8+ CD44− cells were sorted by BD FACSAria II. For OTI Trm cell sorting, 1.5 μg 
FITC conjugated anti-CD45 mice were injected i.v. 5 minutes before mice were scarified. 
OTI cells were enriched by CD8a (Ly-2) MicroBeads (Miltenyi Biotech), and stained with 
BV421 conjugated anti-CD8a, APC conjugated anti-CD90.1, and PE conjugated anti-
CD90.2. Trm cells were sorted based on (i.v. CD45−) CD8+CD90.1+CD90.2− or (i.v. 
CD45−) CD8+CD90.1+CD90.2+.
Chromatin Immunoprecipitation: 10 × 106 activated wild-type or Bhlhe40 deficient CD8+ 
T cells were cross linked with 1% formaldehyde and lysed by sonication (Yao et al., 2013). 
Cell lysis were incubated with Anti-Histone H3 (acetyl K27) (2 μg/sample), Anti-Histone 
H3 (acetyl K9) (2 μg/sample), BHLHE40 antibody (10 μg/sample) or normal rabbit IgG. 
The immunocomplexes were precipitated with Protein A agarose beads at 4°C for 2 hr, 
washed, and eluted and cross-links were reversed at 65°C overnight. DNA was purified and 
prepared for realtime PCR. Primer sequence: Cox6a1-F: ggtgctgtcagcgtctcggg, Cox6a1-R: 
cgggtacctgaaccctcctcg. Mrps16-F: cgtccgcaccactccagagcc, Mrps16-R: gtagcagtcaaggatcagtc. 
Atp5e-F: tttgcaatgtggttccatcg, Atp5e--R: tcgagcccgctctgagtgac, GzmB-F: 
ctgaatgctctccgctccct, GzmB-R: gagtttggggtgaggggaaa, Itgae-F: acttctggaagacagaaacc, Itgae-
R: caggcgggtctcagtgagtc, and as described previously (Kanda et al., 2016; Peng et al., 2016).
Seahorse analysis: Oxygen consumption rates (OCR) and extracellular acidification rates 
(ECAR) were measured with XFe-24 or XF-P Extracellular Flux Analyzers (Seahorse 
Bioscience). Briefly, sorted CD8+ T cells were planted to the Cell-Tak (3.3 ug/well) coated 
XF 24-well plate or XF 8-well plate, OCR and ECAR were testing in the presence of 
oligomycin (1 μM), FCCP (1 μM), rotenone/antimycin A (0.5 μM) orderly.
RNA-seq: RNA from Sorted CD8+ T cells was extracted using an RNeasy kit (Qiagen) 
following the manufacturer’s instructions. After quality control, High quality total RNA was 
used to generate the RNA sequencing library. cDNA synthesis, end-repair, A-base addition, 
and ligation of the Illumina indexed adapters were performed according to the TruSeq RNA 
Sample Prep Kit v2 (Illumina, San Diego, CA). The concentration and size distribution of 
the completed libraries was determined using an Agilent Bioanalyzer DNA 1000 chip (Santa 
Clara, CA) and Qubit fluorometry (Invitrogen, Carlsbad, CA). Paired-end libraries were 
sequenced on an Illumina HiSeq 4000 following Illumina’s standard protocol using the 
Illumina cBot and HiSeq 3000/4000 PE Cluster Kit. Base-calling was performed using 
Illumina’s RTA software (version 2.5.2). Paired-end RNA-seq reads were aligned to the 
mouse reference genome (GRCm38/mm10) using RNA-seq spliced read mapper Tophat2 
(v2.1.1). Pre- and post-alignment quality controls, gene level raw read count and ormalized 
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read count (i.e. FPKM) were performed using RSeQC package (v2.3.6) with NCBI mouse 
RefSeq gene model. RNA-seq data were deposited in GEO database (GEO: GSE135278).
Apoptotic cell detection: CellEvent™ Caspase-3&7 Green Flow Cytometry Assay Kit (Life 
Technologies) was used to detect Caspase 3 and 7 activities inside the cells. Lung, spleen or 
tumor cells were incubated with CellEvent Caspase3&7 green detection reagent for 25 
minutes at 37 degree as described in the manual.
Epigenetic screen: CD8+ T cells from IFNγ-eYFP reporter mice (GREAT) were purified 
with the CD8a (Ly-2) MicroBeads (Miltenyi Biotech), and co-cultured with BMDC in 
presence of anti-CD3 (1 μg / ml) for 2.5 days, then compounds from Epigenetics Screening 
Library (Cayman chemical) were added into culture-system (10 μΜ each). Cells were 
harvested 24 hours later. YFP fluorescence and viability were analyzed by flow cytometer.
Intracellular staining, antibodies and flow cytometry: Cell suspensions were stained with 
indicated surface marker, staining was performed at 4 °C for 30 min. Cells were washed 
twice with FACS buffer (PBS, 2 mM EDTA, 2% FBS, 0.09% Sodium Azide), prior to 
fixation and permeabilization with either Perm Fix and Perm Wash (Biolegend, for cytokine 
staining) or the Foxp3 transcription factor staining buffer set (eBioscience, for KI-67 and 
AceH3 staining) in the dark. Cells were washed twice with perm wash (biolegend or 
eBioscience), stained with Abs for at least 30 min at RT and then washed twice with perm 
wash before flow cytometry acquisition. FACS Abs were primarily purchased from 
Biolegend, BD Biosciences or eBioscience. The clone number of those Abs as follows: 
CD8a (53-6.7), CD8β (YTS156.7.7), CD45(30-F11), CD90.1(OX-7), CD90.2(53-2.1), 
PD-1(29F.1A12), TIM-3(RMT3-23), CTLA4(UC10-4B9), CD103(2E7), CD69(H1.2F3), 
IFN-γ(XMG1.2), TNF-α(MP6-XT22), GzmB(GB11), MIP1-α(DNT3CC), MIP1 
β(FL34Z3L),KI-67(SolA15), human CD8a(HIT8a), human PD1(EH12.2H7), human 
CD11a(HI111), human CD45RO(UCHL1).The dilution of surface staining Abs was 1:200 
and dilution of intracellular staining Abs was 1:100. H2-Db-NP366-374 and H2-Db-PA224-233 
tetramers were obtained from NIH tetramer facility. For prime-flow (eBioscience) staining, 
cells were stained with zombie dye (Biolegend) first then surface and intracellular staining 
were performed following instruction, then human or mouse RNA probes were hydrated and 
labeled with fluorescence dye. After Ab staining, cells were acquired through an 11-color 
Attune NXT system (Life Technologies). Data were then analyzed by FlowJo software 
(Treestar).
Antibody blockade in vivo: Anti-PD-L1 and control Abs were purchased from Bio-X-Cell. 
For systemic PD-L1 blockade in tumor model, WT B6 mice bearing B16-OVA melanoma 
received intraperitoneal injection of control or blocking Abs at the dose of 200 μg/ mouse 
for the first time at 5 days post tumor implantation, mice were then received intraperitoneal 
injection of Abs every 3 days with 50 μg/mouse thereafter. For measurement of Bhlhe40 
expression following intratumor PD-L1 blockade, α-PD-L1 injection was performed at the 
dose of 30 μg/ mouse at 6 days post tumor implantation, the blockade was applied every 3 
days. For the depletion of circulating CD8+ T cells, mice were received 50μg/ mouse anti-
CD8a antibody at 21 d.p.i. For blocking CD8+ T cells circulation, mice were received with 
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FTY720 (20μg/ mouse) daily since 21 d.p.i.. Peripheral CD8+ T cells were checked in the 
PBMC one day before mouse sacrifice.
Transmission electron microscopy: CD8+ T cells from in vitro culture, tumor implanted 
mice or influenza infected mice were isolated as indicated in the text. Cells were then fixed 
in Trump’s Fixative, embedded and sliced for electron microscopy scanning. Quantitative 
analysis of mitochondrial damage was performed by blind review of two investigators on 
enlarged electron microscopy images (from n= 8-10 mice). Structurally abnormal 
mitochondria were defined operationally as those with loss of cristae, disarrayed cristae, 
decreased electron density of the matrix, loss of integrity of mitochondrial membrane and/or 
the formation of autophagosomes structures as reported before (Sohn et al., 2013; Wang et 
al., 2010).
Cellular therapy: For treatment at 6 d.p.t.i., B16-OVA cells (5 χ 105) were implanted 
subcutaneously into C57BL/6 mice. On day 6 post implantation, tumor bearing mice with 
similar tumor size were divided into 4 groups randomly, and received with PBS, in vitro 
activated WT OTI cells (3 d.p.a. following in vitro activation, 1 million cells/mouse) or in 
vitro activated Bhlhe40−/− OTI cells (3 d.p.a. following in vitro activation, 1 million cells/
mouse) or in vitro activated Bhlhe40−/− OTI cells (3 d.p.a. following in vitro activation, 1 
million cells/mouse) treated with Tubastatin A (10 μΜ, TA) (Selleckchem) and Sodium 
Acetate (20μΜ, Ac) (Sigma). Ac and TA were added to the culture at day 2 and 2.5 post 
activation respectively. Cells were washed with PBS before transferred into B16-OVA 
bearing mice at 6 d.p.t.i. After T cell transfer, tumor size was measured every two days. For 
cellular therapy of WT T cells into mice with large tumor burdens, WT OTI cells were 
activated in vitro (3 d.p.a.) and treated with TA and Ac as above. Cells (1 million cells/
mouse) were washed with PBS before transferred into B16-OVA bearing mice at 10 or 12 
d.p.t.i. as indicated in the text.
Checkpoint blockade and chemical therapy: 11 days after B16-OVA tumor implantation, 
mice were intratumorally injected with anti-PD-L1 (30 μg / mouse) every 3 days. Sodium 
acetate (100 nmol/mouse) plus Tubastatin A (60 μg / mouse) were directly injected 
intratumorally daily from 11 days post B16-OVA tumor or 15 days post MC38 tumor 
implantation. Tumor size was calculated as length χ width. Mice with tumor size larger than 
400 mm2 or ulcerative were euthanized and considered as mortality caused by tumor.
Nanostring analysis: Total RNA from sorted T cell populations (n=4-12 mice/group) was 
extracted with mini RNA-easy Kit (Qiagen). Equal amount of total RNA from different cells 
was used for the assay. Hybridization reaction was established by following the instruction 
of manufacture. Aliquots of Reporter Codeset and Capture probeset were thawed at room 
temperature. Then a master of mix was created by adding 70ul of hybridization buffer to the 
tube containing the reporter codeset. 8 μl of this master mix was added to each of tubes for 
different samples, 5 μl (50 ng) of total RNA sample was added into each tube. Then 2 μl of 
well mixed Capture probeset was added to each tube and placed in the preheated 65°C 
thermal cycler. All the sample mixes were incubated for 16 hours at 65°C for completion of 
hybridization. The samples were then loaded into the sample hole in the cartridge and loaded 
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into the NanoString nCounter SPRINT Profiler machine (NanoString). When corresponding 
RLF running is finished, the raw data was downloaded and analyzed with Nanostring 
software nSolver 3.0 (Nanostring). mRNA counts were processed to account for 
hybridization efficiency, background noise, and sample content, and were normalized using 
the geometric mean of housekeeping genes. Fold changes were calculated comparing the 
experimental group to their appropriate controls.
Stable isotope tracer analysis (SITA) analysis: WT or Bhlhe40−/− CD8+ T cells were 
activated in vitro for 3.5 days, then the culture medium was replaced with medium which 
contains [13C-3]-pyruvate or [13C-5]-glutamine, incubating overnight. Cells were washed 
twice with PBS following removing culture medium, then cells were suspended with PBS/
Methanol (1:1) for GC/MS analysis.
Metabolite analysis:  For qualitative large-scale profiling of metabolites, (5 million) WT or 
Bhlhe40−/− CD8+ T cells were activated in vitro for 4 days, Cells pellet was lyzed in 1xPBS 
and was deproteinized with acetonitrile:methanol (1:1 ratio). The supernatants were dried 
down using a stream of nitrogen gas for analysis on a Quadrupole Time-of-Flight Mass 
Spectrometer (Agilent Technologies 6550 Q-TOF) coupled with an Ultra High Pressure 
Liquid Chromatograph (1290 Infinity UHPLC Agilent Technologies).
Profiling data was acquired under both positive and negative electrospray ionization 
conditions over a mass range m/z of 100 – 1700 at a resolution of 10,000 (separate runs) in 
scan mode. Metabolite separation was achieved using two columns of differing polarity, a 
hydrophilic interaction column (HILIC, ethylene-bridged hybrid 2.1 × 150 mm, 1.7 mm; 
Waters) and a reversed-phase C18 column (high-strength silica 2.1 × 150 mm, 1.8 mm; 
Waters).
For TCA-analytes testing, in vitro activated CD8+ T cell pellets (2 million) was lyzed 
acidified 1X PBS after spiking in internal solution containing U-13C labeled analytes. The 
proteins were removed by methanol and acetonitrile. After drying, the sample was 
derivatized with ethoxime and then with MtBSTFA + 1% tBDMCS (N-Methyl-N-(t-
Butyldimethylsilyl)-Trifluoroacetamide + 1% t-Butyldimethylchlorosilane) before it was 
analyzed on an Agilent 5975C GC/MS (gas chromatography/mass spectrometry) under 
electron impact and single ion monitoring conditions. Concentrations of lactic acid (m/z 
261.2), fummaric acid (m/z 287.1), succinic acid (m/z 289.1), oxaloacetic acid (m/z 346.2), 
ketoglutaric acid (m/z 360.2), malic acid (m/z 419.3), aspartic acid (m/z 418.2), 2-
hydroxyglutaratic acid (m/z 433.2), cis aconitic acid (m/z459.3), citric acid (m/z 591.4), and 
isocitric acid (m/z 591.4), glutamic acid (m/z 432.4) were measured against a 7-point 
calibration curves that underwent the same derivatization.
Statistical Analysis: Statistical analysis was done using GraphPad Prism 7.0 (GraphPad 
Software) and presented as means ± SEM. Unpaired or paired Student t tests and one-way or 
two-way ANOVA analysis were used in data analysis. Ap value <0.05 was considered 
statistically significant. * p < 0.05. **p < 0.01, ***p < 0.001,****p <0.0001.
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• Bhlhe40 is required for Trm cell and TIL fitness and function.
• Bhlhe40 is critical for TIL reinvigoration following anti-PD-L1 blockade.
• Bhlhe40 programs Trm cell and TIL mitochondrial metabolism and active 
chromatin state.
• Epigenetic targeting Trm cell and TIL functional program promotes tumor 
control.
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Figure 1. Increased Bhlhe40 expression in tissue-resident CD8+ T cells
(A) RNA-seq analysis of differentially expressed genes in activated WT vs. Bhlhe40−/− 
CD8+ T cells (4 days post activation, d.p.a.).
(B) GSEA of the core tissue-residency signature genes of Trm cells and TILs in WT or 
Bhlhe40−/− CD8+ T cells.
(C) GSEA of the core tissue-residency signature genes of Trm cells and TILs in BHLHE40hi 
or BHLHE40low TILs from colorectal cancer patients.
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(D) RNA-seq analysis of Tmem-SPL vs. lung Trm cells post PR8-OVA infection (42 d.p.i.), 
or TILs vs. splenic CD8+ T cells (T-SPL) post B16-OVA transplantation (12 d.p.t.i.).
(E) GSEA of Bhlhe40-associated gene set in Trm cells vs. Tmem-SPL cells, or TILs vs. T-
SPL.
(F) Left, MFI of BHLHE40 in tumor-reactive PBMC CD8+ T cells or TILs from RCC 
patients (n=6); right, BHLHE40 expression in human lung CD8+ Trm cells or PBMC Tmem 
cells.
(G) GSEA of BHLHE40-associated gene set in TILs or PBMC CD8+ T cells from colorectal 
cancer, liver cancer (HCC) and lung cancer (NSCLC) patients.
*P≤ 0.05 (Student’s t-test). See also Figure S1.
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Figure 2. Bhlhe40 maintains function and survival of Trm cells
(A) % NP366-374+ Teff-Lung or Teff-SPL of WT or Bhlh40−/− mice following X31 infection 
at 10 d.p.i. (n=10, 2 experiments).
(B) % NP366-374+ Trm, lung circulating T memory (Tmem-Cir) or Tmem-SPL cells of WT 
or Bhlh40−/− mice following X31 infection at 39 d.p.i. (n=12-14, 3 experiments).
(C) and (D), % NP366-374 + and PA224-233+ Trm or Tmem-SPL cells from WT or Bhlh40−/− 
mice at 42 d.p. PR8 infection (n=11, 2 experiments ).
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(E) % apoptotic (Caspase 3&7 FLICA+) NP366-374+ Trm cells at 42 d.p. PR8 infection (n= 
5).
(F-H) WT and Bhlhe40−/− OTI cells were 1:1 mixed and transferred into recipient mice 
infected with PR8-OVA (n=12, 2 experiments). Representative plots (F) and ratio (G) of WT 
to Bhlhe40−/− OTI cells in the lung and spleen were evaluated at 10 and 35 d.p.i. (H) %IFN-
γ+ OTI cell after ex vivo peptide stimulation.
(I, J) Representative plots (I) and % (J) NP366-374 + or PA224-233+ Trm cells in Bhlhe4(f/f or 
Bhlhe40ΔT mice at 42 d.p. PR8 infection (n=8-9, 2 experiments).
(K) % IFN-γ+ Trm or Tmem-SPL cells at 42 d.p. PR8 infection (n=8, 2 experiments).
(L) WT or Bhlh40−/− mice were infected with X31 and re-challenged with PR8 in the 
presence of FTY-720 at 45 d.p.i. % original weight was determined (n=3-4).
(M) Bhlhe40f/f or Bhlhe40ΔT mice were infected with PR8 and re-challenged with X31 in 
the presence of FTY-720 at 42 d.p.i. % body weight before rechallenge was determined 
(n=5-7).
Representative data from 2 or 3 experiments except those data from pooled experiments. 
*P≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****p < 0.0001 (Student’s t-test). See also Figure S2.
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Figure 3. Bhlhe40 governs TIL responses and functionality
(A) TIL density (CD8+ T cell #/mg tumor tissue) in B16-OVA tumor bearing WT or 
Bhlhe40−/− mice (n=3).
(B) % OVA257-264+ CD8+ T cells in tumor or spleen (n=4-9, 2 experiments).
(C) Representative plots and % apoptotic (Caspase3&7 FLICA+) CD8+ T cells from tumor 
or spleen (n=7, 2 experiments).
(D) % IFN-γ+ or GzmB+ CD8+ T cells from tumor or spleen of WT or Bhlhe40−/− mice (14 
d.p.t.i.) (n=10, 2 experiments).
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(E) The production of IFN-γ, TNF-α, GzmB, CCL3 and CCL4 by TILs (14 d.p.t.i.) were 
measured following ex vivo stimulation. After Boolean gating, individual populations were 
grouped based on the total number of effector molecules producing cells (n= 4-6).
(F-H) Indicated tumor growth curves (F (n=15-16, 4 experiments) and G (n=4)) or tumor 
weight (H) (n=4-5) in WT or Bhlhe40−/− mice.
(I) WT and Bhlhe40−/− OTI cells were 1:1 mixed and transferred into B16-OVA bearing 
mice. Ratio of WT to Bhlhe40−/− OTI cells was evaluated (n=8-9, 2 experiments).
(J-M) Bhlhe40f/f or Bhlhe40ΔT mice were transplanted with B16-OVA. (J) % OVA257-264+ 
TILs at 14 d.p.t.i (n=5). (K) % CD69+CD103+ TILs at 14 d.p.t.i. in bulk or OVA specific 
TILs (n=5). (L) Cytokine and effector molecule production by TILs (n=8, 2 experiments). 
(M) B16-OVA growth curves (left) (n=14, 3 experiments) and tumor weight (right) (n=10, 2 
experiments).
(N, O) B16-OVA bearing WT mice received OTI cells transduced with control (Vector) or 
Bhlhe40-expressing retrovirus (Bhlhe40 O.E.) at 5 d.p.t.i. (N) Cell counts of transferred cells 
inside tumor at 12 d.p.t.i. (O) Tumor weight (n=4-5).
Representative data from 2 to 4 experiments except those data from pooled experiments. *P≤ 
0.05,**P ≤ 0.01, ***P ≤ 0.001 (Student’s t-test and Two-way ANOVA). See also Figure S3.
Li et al. Page 30













Figure 4. Bhlhe40 is required for T cell reinvigoration following PD-L1 blockade
(A) B16-OVA were implanted into both sides of flank following with intratumor injection of 
α-PD-L1 or control IgG to one side. MFI of Bhlhe40 from TILs at 14 d.p.t.i. (n=9, 2 
experiments).
(B-D) WT or Bhlhe40−/− B16-OVA bearing mice received control IgG or α-PD-L1 from 5 
d.p.t.i. % IFN-γ+ TILs (B) or % apoptotic TILs (C) from indicated groups at 15 d.p.t.i. (n=9, 
2 experiments). (D) Tumor growth curve (n=13-15, 3 experiments).
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(E-G) Bhlhe40f/f or Bhlhe40ΔT B16-OVA bearing mice received control IgG or α-PD-L1 
from 5 d.p.t.i. % IFN-γ+ TILs (E) or % apoptotic TILs (F) from indicated groups at 16 
d.p.t.i. (G) Tumor growth curves (n=5).
Representative data from 2 or 3 independent experiments except those data from pooled 
experiments. *P≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 (Student’s t-test and Two-way ANOVA). 
See also Figure S4.
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Figure 5. Bhlhe40 programs mitochondrial and epigenetic regulation of Trm cells and TILs
(A) WT or Bhlhe40−/− OTI cells were transferred into WT mice and infected with PR8-
OVA. OTI Trm cells were sorted for RNA-seq at 42 d.p.i., KEGG pathway analysis of genes 
down-regulated in Bhlhe40−/− Trm cells.
(B) GSEA of mitochondrial energy metabolism or OXPHOS genes in WT vs. Bhlhe40−/− 
Trm cells.
(C) Heat map of mitochondrial complex gene expression in WT or Bhlhe40−/− Trm cells.
(D) Binding of Bhlhe40 to indicated mitochondrial genes in activated CD8+ T cells.
Li et al. Page 33













(E) Basal OCR or ECAR of WT or Bhlhe40−/− Trm cells at 42 d.p.i. (n= 3).
(F) Electron microscope (EM) images of mitochondria in WT or Bhlhe40−/− Trm or Tmem-
SPL cells (scale bars,300 nm) (left). Damaged mitochondria counts per cell from each group 
(right).
(G) EM images of mitochondria in WT or Bhlhe40−/− TILs (scale bars, 200 nm) (left). 
Damaged mitochondria counts per cell from each group (right).
(H) Down-regulated metabolic pathways in in vitro activated Bhlhe40−/− CD8+ T cells 
compared to WT (4 d.p.a., n= 3).
(I) TCA cycle metabolites measured by GC/MS (concentration/million cells) in in vitro 
activated WT or Bhlhe40−/− CD8+ T cells (4 d.p.a.) (n=5).
(J) Acetyl-CoA concentrations in in vitro activated WT or Bhlhe40−/− T cells (4 d.p.a.) (n=6, 
2 experiments).
(K) Acetyl-histone H3 of in vitro activated CD8+ T cells (4 d.p.a.), Trm cells (42 d.p.i.) or 
TILs (14 d.p.t.i.) from WT or Bhlhe40−/− mice (n=3-6).
(L) H3K9Ac (left) or H3K27Ac (right) at Ifng promoter were accessed by ChIP from in 
vitro activated CD8+ T cells (4 d.p.a.).
Representative data from 2 or 3 independent experiments except those data from pooled 
experiments and (A), (B), (G), (H) & (I). *P≤ 0.05,**P ≤ 0.01 (Student’s t-test). See also 
Figure S5.
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Figure 6. Identification of an epigenetic and metabolic regimen promoting CD8+ T cell residency 
genes and functionality
(A) Schematics of epigenetic screening approach (top), heat map of IFN-γ-YFP 
fluorescence and cell viability of the T cells following screen (bottom).
(B) IFN-γ YFP expression following treatment of indicated epigenetic modifiers.
(C) % IFN-γ+ CD8+ T cells after treatment with vehicle (Veh), Tubastain A (TA), Acetate 
(Ac) or TA plus Ac (TA/Ac) at 3 d.p.a.
(D) Activated WT or Bhlhe40−/− CD8+ T cells treated with Veh, TA, Ac or TA/Ac. The 
production of IFN-γ, TNF-α, GzmB, CCL3 and CCL4 was measured.
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(E) Heat map of effector molecule genes in WT or Bhlhe40−/− CD8+ T cells (4 d.p.a.) 
following Veh or TA/Ac treatment (by Nanostring).
(F) Heat map of genes associated with Trm cell and TIL residency in WT or Bhlhe40−/− 
CD8+ T cells (4 d.p.a.) following Veh or TA/Ac treatment (by Nanostring).
(G) GSEA of upregulated genes shared by WT and Bhlhe40−/− CD8+ T cells after TA/Ac 
treatment ( > 1.5 fold) in WT Trm vs. Tmem-SPL.cells
(H) Activated WT or Bhlhe40−/− OTI cells were treated with or without TA/Ac. Ace-H3 was 
measured in indicated groups.
(I) H3K9Ac at Ifng, Gzmb and Itgae promoter with or without TA/Ac treatment in vitro at 4 
d.p.a.
Representative data from 2 or 3 independent experiments except (E), (F) & (G). See also 
Figure S6.
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Figure 7. Tubastatin A and acetate treatment promotes antitumor activities of CD8+ T cells
(A) B16-OVA bearing WT mice received PBS, WT effector OTI cells, Bhlhe40−/− effector 
OTI cells treated with Veh or TA/Ac at 6 d.p.t.i. (tumor < 45 mm2). Tumor growth curves 
(n= 6-12, 2 experiments).
(B) B16-OVA bearing WT mice received PBS, WT effector OTI cells treated with Veh or 
TA/Ac at 12 d.p.t.i (tumor > 120 mm2). Tumor growth and survival curves (n=9-10, 2 
experiments).
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(C, D) WT mice were treated with Veh or TA/Ac intratumorally from 11 d.p.t.i. (tumor > 
100 mm2). MFI of acetylated histone H3 (C), and % IFN-γ+ or CCL3+ cells (D) in TILs at 
13 d.p.t.i. (n=3).
(E) B16-OVA growth and survival curves of mice that received intratumoral injection with 
α-PD-L1, Veh or TA/Ac from 11 d.p.t.i. (tumor > 100 mm2) (n=8).
(F) MC38 growth and survival curves of mice that received intratumoral Veh or TA/Ac 
injection from 15 d.p.t.i. (tumor > 100 mm2) (n=10, 2 experiments).
(G) B16-OVA were implanted into both sides of flank of WT mice followed with 
intratumoral injection of TA/Ac or Veh to one side at 10 d.p.t.i. Tumor growth curves of the 
two sides (n=6).
(H) B16-OVA were implanted into both sides of flank of Bhlhe40ΔT mice followed with 
intratumoral injection of TA/Ac or Veh to one side at 10 d.p.t.i. Tumor weight of the two 
sides at 15 d.p.t.i. (n=6).
(I) B16-OVA growth and survival curves of mice that received anti-CD8a or IgG at 1 day 
before intratumorally injection of Veh or TA/Ac from 11 d.p.t.i. (tumor > 100 mm2) (n=5-9, 
2 experiments).
Representative data from 2 or 3 experiments except those data from pooled experiments and 
H. *P≤ 0.05,**P≤ 0.01, ***P ≤ 0.001, ****p < 0.0001 (Student’s t-test and Two-way 
ANOVA). See also Figure S7.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
APC/Cy7 anti-mouse CD8a Antibody BioLegend Cat. No. 100714, RRID: AB_312753
FITC anti-mouse CD8b Antibody BioLegend Cat. No. 126606, RRID: AB_961295
PerCP/Cyanine5.5 anti-mouse CD45 Antibody BioLegend Cat. No. 103132, RRID: AB_893340
PE anti-rat CD90/mouse CD90.1 (Thy-1.1) Antibody BioLegend Cat. No. 202524, RRID: AB_1595524
APC anti-mouse CD90.2 (Thy-1.2) Antibody BioLegend Cat. No. 140312, RRID: AB_10640728
Brilliant Violet 711™ anti-mouse CD279 (PD-1) Antibody BioLegend Cat. No. 135231, RRID: AB_2566158
Brilliant Violet 421™ anti-mouse CD366 (TIM-3) Antibody BioLegend Cat. No. 119723, RRID: AB_2616908
PerCP/Cyanine5.5 anti-mouse CD152 Antibody BioLegend Cat. No. 106316, RRID: AB_2564474
PE/Cy7 anti-mouse CD103 Antibody BioLegend Cat. No. 121426, RRID: AB_2563691
Brilliant Violet 510™ anti-mouse CD103 Antibody BioLegend Cat. No. 121423, RRID: AB_2562713
FITC anti-mouse CD69 Antibody BioLegend Cat. No. 104506, RRID: AB_313109
PE Anti-Mouse IFN gamma BioLegend Cat. No. 505808, RRID: AB_315402
Brilliant Violet 510™ anti-mouse TNF-α Antibody BioLegend Cat. No. 506339, RRID: AB_2563127
Pacific Blue™ anti-human/mouse Granzyme B Antibody BioLegend Cat. No. 515408, RRID: AB_2562196
CCL3 (MIP-1 alpha) Monoclonal Antibody (DNT3CC), eFluor 
660, eBioscience™
ThermoFisher Cat. No. 50-753282, RRID: AB_2574295
CCL4 (MIP-1 beta) Monoclonal Antibody (FL34Z3L), PerCP-
eFluor 710, eBioscience™
ThermoFisher Cat. No. 46-754042, RRID: AB_2573845
Ki-67 Monoclonal Antibody (SolA15), PE-Cyanine7, 
eBioscience™
ThermoFisher Cat. No. 25-569882, RRID: AB_11220070
PE/Cy7 anti-human CD8a Antibody BioLegend Cat. No. 300914, RRID: AB_314118
Brilliant Violet 421™ anti-human CD279 (PD-1) Antibody BioLegend Cat. No. 329920, RRID: AB_10960742
PE anti-human CD11 a Antibody BioLegend Cat. No. 301208, RRID: AB_314146
Brilliant Violet 605™ anti-human CD45RO Antibody BioLegend Cat. No. 304238, RRID: AB_2562153
InVivoMAb anti-mouse PD-L1 (B7-H1) BioXCell Cat. No. BE0101 RRID: AB_10949073
InVivoMAb anti-mouse CD3ε BioXCell Cat. No. BE0261 RRID: AB_2687740
InVivoMAb anti-mouse CD28 BioXCell Cat. No. BE0015-5 RRID: AB_1107628
InVivoMAb polyclonal Rat IgG BioXCell Cat. No. BE0094
Anti-acetyl-Histone H3 Antibody Millipore Cat. No. 06-599
Anti-ATP citrate lyase antibody abcam Cat. No. ab40793
PE Donkey anti-rabbit IgG (minimal x-reactivity) Antibody BioLegend Cat. No. 406421 RRID: AB_2563484
DEC1 Antibody NOVUS Cat. No. NB100-1800
Anti-Histone H3 (acetyl K9) antibody abcam Cat. No. ab4441
Anti-Histone H3 (acetyl K27) antibody abcam Cat. No. ab4729
Bacterial and Virus Strains
Influenza A/PR8/34
Laboratory of Thomas 
Braciale
(Sun et al., 2011; Sun et al., 2009)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Influenza A/X-31
Laboratory of Thomas 
Braciale
(Sun et al., 2011)
Influenza A/PR8-OVA Laboratory of Thomas 
Braciale
Biological Samples
Tumor tissue and PBMC from RCC patients Mayo Clinic, https://www.mayoclinic.org/
Tumor tissue and PBMC from RCC patients Vanderbilt University Medical 
Center
https://ww2.mc.vanderbilt.edu/
Chemicals, Peptides, and Recombinant Proteins
Influenza NP366 Tetramer NIH Tetramer Facility Cat# H-2D(b) ASNENMETM
Influenza PA224 Tetramer NIH Tetramer Facility Cat# H-2D(b) SSLENFRAYV
OVA257 Tetramer NIH Tetramer Facility Cat# H-2K(b) SIINFEKL
Collagenase Type 2 Worthington Biochemical Cat# LS004177
Fetal Bovine Serum HyClone Cat# SH30070.03
RPMI 1640 GIBCO Cat# 11875-093
Dulbecco’s modified Eagle’s medium Corning Cat# 10-017-CV
Penicillin-Streptomycin-Glutamine (10,000 U/mL) GIBCO Cat# 10378-016
Phosphate-Buffered Saline, 1X Corning Cat# 21-040-CV
On-Column DNase I Digestion Set Sigma-Aldrich Cat# DNASE70
FTY720 Cayman Chemical Cat# 10006292
Corning™ Cell-Tak Cell and Tissue Adhesive Corning™ Cat# CB40240
Monensin Solution (1,000X) BioLegend Cat# 420701
Influenza A NP (366 - 374) Strain A/NT/60/68 
ASNENMDAM
Anaspec Cat# AS-60623
OVA (257 - 264) SIINFEKL Anaspec Cat# AS-60193-5
Lung Dissociation Kit, mouse Miltenyibiotec Cat# 130-095-927
Tumor Dissociation Kit, mouse Miltenyibiotec Cat# 130-096-730
CD8a (Ly-2) MicroBeads, mouse Miltenyibiotec Cat# 130-117-044
Sodium acetate trihydrate Sigma-Aldrich Cat# S7670
Tubastatin A Selleckchem Cat# S8049
Sodium Pyruvate (100 Mm) GIBCO Cat# 11360070
Sodium citrate dihydrate Sigma-Aldrich Cat# W302600
Epigenetics Screening Library Cayman Cat# 11076 Batch# 04980804
Recombinant Mouse IL-1β (carrier-free) BioLegend Cat# 575106
Recombinant Mouse IL-15 (carrier-free) BioLegend Cat# 566304
Recombinant Mouse IL-21 (carrier-free) BioLegend Cat# 574506
Recombinant Mouse IL-7 (carrier-free) BioLegend Cat# 577806
Recombinant Mouse IL-33 (carrier-free) BioLegend Cat# 580506
Recombinant Mouse TNF-α (carrier-free) BioLegend Cat# 575206
Recombinant Mouse TGF-β1 (carrier-free) BioLegend Cat# 763104
Recombinant Mouse IL-10 (carrier-free) BioLegend Cat# 575806
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REAGENT or RESOURCE SOURCE IDENTIFIER
Prostaglandin E2 (PGE2) R&D systems Cat# 2296/10
Critical Commercial Assays
GenElute™ Mammalian Total RNA Miniprep Kit Sigma-Aldrich Cat# RTN350
RNeasy Mini Kit QIAGEN Cat# 74104
Fast SYBR Green Master Mix Applied Biosystems Cat# 4385612
M-MLV Reverse Transcriptase Invitrogen Cat# 28025-021
eBioscience™ Foxp3 / Transcription Factor Staining Buffer 
Set Thermo Fisher Scientific Cat# 00-5523-00
Intracellular Staining Permeabilization Wash Buffer (10X) BioLegend Cat# 420801
Fixation Buffer BioLegend Cat# 421002
nCounter® Mouse Immunology Panel NanoString Technologies Cat# XT-CSO-MIM1-12
PrimeFlow™ RNA Assay Kit ThermoFisher Cat# 88-18005-210
CellEvent™ Caspase-3&7 Green Flow Cytometry Assay Kit ThermoFisher Cat# C10427
Dimethyl α-ketoglutarate Sigma Aldrich Cat# 349631
Methyl pyruvate Sigma Aldrich Cat# 371173
SODIUM PYRUVATE (13C3, 99%) Cambridge Isotope 
Laboratories
Cat# CLM-2440-0.5
L-GLUTAMINE (13C5, 99%) Cambridge Isotope 
Laboratories
Cat# CLM-1822-H-0.1
Acetyl CoA Assay Kit abcam Cat# ab87546
Seahorse XFe/p FluxPaks Agilent Cat# 102340-100 103022-100
Seahorse XF Cell Mito Stress Test Kit Agilent Cat# 103015-100
ATP Determination Kit ThermoFisher Cat# A22066
Deposited Data
Raw and analyzed RNA-seq data This paper GEO: GSE135278
Single cell RNA-seq of T cells in colorectal cancer Zhang et al., 2018 EGAS00001002791
RNA-seq of Trm cell of lung from human Hombrink et al., 2016 GEO: GSE61397
Experimental Models: Cell Lines
B16-OVA Laboratory of Haidong Dong (Dronca et al., 2016)
MC38 Laboratory of Haidong Dong (Tang et al., 2018)
LLC Laboratory of Haidong Dong
Experimental Models: Organisms/Strains
C57BL/6J The Jackson Laboratory Cat# 000664
CD90.1 (Thy 1.1) The Jackson Laboratory Cat# 000406
OT-I The Jackson Laboratory Cat# 003831
CD4-Cre The Jackson Laboratory Cat# 017336
Flp The Jackson Laboratory Cat# 005703
Bhlhe40tm1a(KOMP)Wtsi MMRRC Cat# 88443
IFN-γ-YFP (GREAT) The Jackson Laboratory Cat# 017580
Bhlhe40−/− Laboratory of Brian T. 
Edelson













Li et al. Page 42
REAGENT or RESOURCE SOURCE IDENTIFIER
Pdcd1−/− Laboratory of Haidong Dong
Oligonucleotides
Hprt-F: CTCCGCCGGCTTCCTCCTCA This paper
Hprt-R:ACCTGGTTCATCATCGCTAATC This paper
Acly-F: TTCGTCAAACAGCACTTCC This paper
Acly-R: ATTTGGCTTCTTGGAGGTG This paper
Bhlhe40 primers IDT Cat# Mm.PT.58.10417747
Cox6a1-F: ggtgctgtcagcgtctcggg This paper
Cox6a1-R: cgggtacctgaaccctcctcg This paper
Mrps16-F: cgtccgcaccactccagagcc This paper
Mrps16-R: gtagcagtcaaggatcagtc This paper
Atp5e-F: tttgcaatgtggttccatcg This paper
Atp5e-R: tcgagcccgctctgagtgac This paper
GzmB-F: ctgaatgctctccgctccct This paper
GzmB-R: gagtttggggtgaggggaaa This paper
Itgae-F: acttctggaagacagaaacc This paper
Itgae-R: caggcgggtctcagtgagtc This paper
Infg locus for Chip-PCR Kabda et al.,2016
Peng et al., 2016
Software and Algorithms
GraphPad Prism 8 GraphPad Software http://www.graphpad.com
FlowJo (version 10.5) LLC http://www.flowjo.com
nSolver 3.0 NanoString Technologies http://www.nanostring.com/
R language https://www.r-project.org/
GSEA Broad Institute http://software.broadinstitute.org/gsea/
index.jsp
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